Deuruxolitinib: New Approval.

IF 3.1 3区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical Drug Investigation Pub Date : 2026-08-01 Epub Date: 2026-07-01 DOI:10.1007/s40261-026-01568-6

Simon Fung

引用次数: 0

Abstract

Deuruxolitinib (LEQSELVI), a deuterated analogue of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib, is being developed by Sun Pharmaceuticals Industries for the treatment of alopecia areata. In July 2024, deuruxolitinib received its first global approval for the treatment of severe alopecia areata in adults in the USA. Additionally, in March 2026, deuruxolitinib received approval in the same indication in the UK. This article summarizes the milestones in the development of deuruxolitinib leading to the approval for severe alopecia areata in adults.

查看原文本刊更多论文

Deuruxolitinib：新批准

Deuruxolitinib （LEQSELVI）是Janus激酶（JAK） 1/2抑制剂ruxolitinib的氘化类似物，由太阳制药工业公司开发用于治疗斑秃。2024年7月，deuruxolitinib在美国获得了首个用于治疗成人严重斑秃的全球批准。此外，2026年3月，deuruxolitinib在英国获得了相同适应症的批准。这篇文章总结了deuruxolitinib发展的里程碑，导致批准用于成人严重斑秃。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Drug Investigation 医学-药学

CiteScore

5.90

自引率

3.10%

发文量

108

审稿时长

6-12 weeks

期刊介绍： Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes: -Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs. -Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice. -Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed. -Studies focusing on the application of drug delivery technology in healthcare. -Short communications and case study reports that meet the above criteria will also be considered. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.